Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention
Seung‐Jun Lee, Jae Hong Joo, Sohee Park, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 5, pp. 401-410
Open Access | Times Cited: 20

Showing 20 citing articles:

2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
Maciej Banach, Stanisław Surma, Peter P. Tóth
Archives of Medical Science (2023)
Open Access | Times Cited: 32
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)
Maciej Banach, Željko Reiner, Stanisław Surma, et al.
Drugs (2024)
Open Access | Times Cited: 9
Therapeutic Inertia in Dyslipidemia Management for Secondary Cardiovascular Prevention: Results from the Italian ITACARE-P Network
Andrea Faggiano, Anna Gualeni, Lucia Barbieri, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 493-493
Open Access | Times Cited: 1
Lipid-lowering in diabetes: An update
Alan Chait, Robert H. Eckel, Michal Vráblík, et al.
Atherosclerosis (2023) Vol. 394, pp. 117313-117313
Open Access | Times Cited: 21
Medications for Lipid Control: Statins vs Newer Drugs
Ruth McPherson, Najah Adreak, Abhinav Sharma
Canadian Journal of Cardiology (2024) Vol. 40, Iss. 8, pp. S26-S34
Open Access | Times Cited: 5
Management of dyslipidemia in coronary artery disease: the present and the future
Kyriakos Dimitriadis, Panagiotis Theofilis, Panagιotis Iliakis, et al.
Coronary Artery Disease (2024) Vol. 35, Iss. 6, pp. 516-524
Closed Access | Times Cited: 4
Approach to Lipid Management in the Patient with Diabetes
Stephanie Kim, Savitha Subramanian
The Journal of Clinical Endocrinology & Metabolism (2025)
Open Access
Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis
Maciej Banach, Vikash Jaiswal, Song Peng Ang, et al.
Mayo Clinic Proceedings (2025)
Closed Access
Real-world management of hypercholesterolemia in patients after acute coronary syndrome in Greece
Despoina Massia, Periklis Giovas, Nikolaos Papadopoulos, et al.
Atherosclerosis Plus (2025) Vol. 60, pp. 20-26
Open Access
Should Patients With Myocardial Infarction Be Started on Combination Therapy With Ezetimibe Before Hospital Discharge?
Clara K Chow, Oliver Archer, Leonard Kritharides
Journal of the American College of Cardiology (2025) Vol. 85, Iss. 15, pp. 1565-1567
Closed Access
Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis
Quankai Cheng, Jingjing Sun, Haicheng Zhong, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
The clinical effectiveness and safety of low/moderate-intensity statins & ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis
Pishoy Sydhom, Bakr Al-Quraishi, Mohamad El-Shawaf, et al.
BMC Cardiovascular Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Closing the Gaps in Care of Dyslipidemia: Revolutionizing Management with Digital Health and Innovative Care Models
Samuel J Apple, Rachel Clark, Jonathan Daich, et al.
Reviews in Cardiovascular Medicine (2023) Vol. 24, Iss. 12, pp. 350-350
Open Access | Times Cited: 5
Upfront Combination of Statin and Ezetimibe for Patients With Acute Coronary Syndrome: Time for a New Approach?
Lina Ya’qoub, Hend Mansoor, Islam Y. Elgendy
Journal of the American Heart Association (2023) Vol. 12, Iss. 18
Open Access | Times Cited: 4
A Nation-Wide Evaluation of Suboptimal Lipid-Lowering Treatment Patterns Among Patients Undergoing Intervention for Acute Coronary Syndrome in Hungary
G Nagy, László Márk, Andrea Gerencser, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6562-6562
Open Access | Times Cited: 1
Real-world evidence evaluation of LDL-C in hospitalized patients: a population-based observational study in the timeframe 2021–2022
Umberto Capece, Chiara Iacomini, Teresa Mezza, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy
Sha Li, Huihui Liu, Jian‐Jun Li
Drugs (2024) Vol. 85, Iss. 1, pp. 51-65
Open Access
Combination Therapy With Lower Statin Dose and the Race to LDL-C Goal
Ori Ben‐Yehuda
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 5, pp. 411-413
Open Access | Times Cited: 1
Optimal Revascularization Timing of Coronary Artery Bypass Grafting in Acute Myocardial Infarction
Hyo‐Hyun Kim, Myeongjee Lee, Kyung‐Jong Yoo
Clinical Cardiology (2024) Vol. 47, Iss. 8
Open Access
A kardiovaszkuláris esemény utáni betegek irányelvek szerinti lipidcsökkentő kezelésének lehetőségei Magyarországon 2023-ban: a fixkombináció prioritása
László Márk, Mária Nagy, Viola Zsuzsanna Papp
Cardiologia Hungarica (2023) Vol. 53, Iss. 5, pp. 491-496
Open Access
Page 1

Scroll to top